Briana Contreras

The FDA's groundbreaking decision to waive clinical efficacy studies for a monoclonal antibody biosimilar revolutionizes drug approval, reducing costs and enhancing patient access.

Two new forms of Trichophyton mentagrophytes type VII and Trichophyton indotineae are emerging, according to a new report.

In a population-based cohort study, researchers explored the mortality of vitiligo as there is limited information about the risks of mortality among these patients.

The World Health Organization shared its enthusiasm for the “appropriate” use of these technologies. However, they are calling for caution to be exercised to protect and promote human well-being, safety, and autonomy and preserve public health.

As a dozen Humira Biosimilars are set to enter the market this year, it seems to be unlikely that they will drive down drug costs in the future.

Results from the test reveal that high levels of the immune biomarker Thymus and Activation-Regulated Chemokine (TARC) in babies increases their chances of developing atopic dermatitis.

Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.

The occurrence of immune-mediated inflammatory diseases (IMID) is higher in patients with inflammatory bowel disease (IBD) than in the general population.

Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.